Indonesia: vaccines market revenue by segment 2029

Significant fluctuations are estimated for all segments over the forecast period for the revenue. Only in the segment Other Vaccines, a significant increase can be observed over the forecast period. In this segment, the indicator exhibits a difference of 147.21 million U.S. dollars between 2020 and 2029.

The Statista Market Insights cover a broad range of additional markets.

Revenue of the vaccines market in Indonesia from 2020 to 2029, by segment (in million U.S. dollars)

Characteristic	COVID-19 Vaccines	Other Vaccines
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Citation formats